1. Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies.
- Author
-
Melamed, Zeev, López-Erauskin, Jone, Beccari, Melinda, Ling, Karen, Zuberi, Aamir, Presa, Maximilliano, Gonzalo-Gil, Elena, Maimon, Roy, Vazquez-Sanchez, Sonia, Chaturvedi, Som, Bravo-Hernández, Mariana, Taupin, Vanessa, Moore, Stephen, Artates, Jonathan, Acks, Eitan, Ndayambaje, I, Agra de Almeida Quadros, Ana, Jafar-Nejad, Paayman, Rigo, Frank, Bennett, C, Lutz, Cathleen, Lagier-Tourenne, Clotilde, Cleveland, Don, and Baughn, Michael
- Subjects
Animals ,Humans ,Mice ,DNA-Binding Proteins ,Polyadenylation ,RNA Precursors ,Stathmin ,TDP-43 Proteinopathies ,RNA Splicing ,RNA Splice Sites ,Gene Editing ,Oligonucleotides ,Antisense ,Neuronal Outgrowth - Abstract
Loss of nuclear TDP-43 is a hallmark of neurodegeneration in TDP-43 proteinopathies, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). TDP-43 mislocalization results in cryptic splicing and polyadenylation of pre-messenger RNAs (pre-mRNAs) encoding stathmin-2 (also known as SCG10), a protein that is required for axonal regeneration. We found that TDP-43 binding to a GU-rich region sterically blocked recognition of the cryptic 3 splice site in STMN2 pre-mRNA. Targeting dCasRx or antisense oligonucleotides (ASOs) suppressed cryptic splicing, which restored axonal regeneration and stathmin-2-dependent lysosome trafficking in TDP-43-deficient human motor neurons. In mice that were gene-edited to contain human STMN2 cryptic splice-polyadenylation sequences, ASO injection into cerebral spinal fluid successfully corrected Stmn2 pre-mRNA misprocessing and restored stathmin-2 expression levels independently of TDP-43 binding.
- Published
- 2023